07/01/1991 - "Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study."
01/01/1987 - "In an ADR-resistant murine L5178Y lymphoma subline sensitivity was improved with ADR and 1 microM VPM, whereas the cytotoxic effects of mitoxantrone or esorubicin were not affected by VPM. "
01/01/1987 - "4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors: first evidence of activity."
09/01/1984 - "A phase I study of 4'deoxydoxorubicin (esorubicin) was performed on an every-21-day bolus intravenous (IV) schedule in 36 patients with advanced cancer. "
05/01/1990 - "Esorubicin (4'-deoxydoxorubicin, DxDx) has undergone extensive Phase II investigation for the treatment of cancer. "
07/01/1989 - "4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. "
01/01/1987 - "A retrospective analysis was performed on the medical charts of 160 cancer patients who received esorubicin (ESO or 4'deoxydoxorubicin) in a Phase I clinical trial. "
01/01/1986 - "As discussed, we feel that further investigation of esorubicin in anthracycline-sensitive tumors is warranted."
04/01/1992 - "Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin. "
11/01/1989 - "Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study."
06/01/1989 - "Phase II trial of esorubicin in advanced renal carcinoma. "
07/01/1987 - "Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group."
04/01/1987 - "Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/1988 - "4'-Deoxydoxorubicin had little activity in non-small-cell lung cancer at the dose used in this study."
09/01/1987 - "Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer."
07/01/1987 - "Phase II trial of esorubicin in patients with advanced non-small cell lung cancer."
11/01/1985 - "Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer."
05/01/1990 - "One hundred thirty-six patients with histologically or cytologically documented non-small cell lung cancer or advanced breast cancer were enrolled in two concurrent CALGB clinical trials using esorubicin at a dose of 30 mg/m2 administered intravenously every 21 days. "
|5.||Breast Neoplasms (Breast Cancer)
06/01/1990 - "Forty-six eligible women with advanced metastatic breast cancer were entered on a Phase II trial utilizing esorubicin (4'-deoxydoxorubicin) given in a dosage of 30 mg/m2 intravenously every 3 weeks. "
11/01/1985 - "Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer."
06/01/1990 - "Esorubicin is an active agent in metastatic breast cancer; its role in treatment remains undefined."
06/01/1990 - "Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. "
01/01/1986 - "Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. "
|4.||Idarubicin (4 Demethoxydaunorubicin)
|7.||acivicin (AT 125)
|1.||Drug Therapy (Chemotherapy)